Mubadala unit acquires Julphar subsidiary
Kelix bio, wholly owned by Mubadala Investment Company, an Abu Dhabi sovereign investor, has completed the acquisition of DiabTec, a subsidiary of Julphar.
This acquisition strengthens Mubadala's portfolio of biologicals, establishes its role in biomanufacturing across the MENA region, and supports its efforts to advance the UAE's life sciences sector through local manufacturing, said Mubadala.
DiabTec's facility includes 20,000-litre drug substance reactors and a separate cartridge fill-finish facility for drug products. The state-of-the-art facility is built to EU/US FDA standards and is currently the only one in the GCC of this kind.
This strategic acquisition aligns with Mubadala's commitment to responsible investing, which focuses on addressing critical global challenges including the growing prevalence of diabetes, and demand for microbial based products such as insulin analogues and GLP-1 to treat such conditions locally and abroad, it said.
Dr Bakheet Al Katheeri, Chief Executive Officer of Mubadala's UAE Investments Platform, said: 'The acquisition of DiabTec by Kelix bio is a significant milestone for Mubadala, further strengthening our nation's position in the global life sciences ecosystem. This strategic investment reflects our commitment to responsible investing, addressing critical global healthcare challenges like the growing need for insulin analogues. Moreover, it strengthens Mubadala's portfolio of biologicals, establishes our role in biomanufacturing across the MENA region, and advances the UAE's life sciences sector through local manufacturing.'
Ismail Ali Abdulla, Executive Director of UAE Clusters at Mubadala's UAE Investments Platform, said: " Mubadala recognizes the critical importance of ensuring reliable access to therapeutic solutions like insulin analogues, particularly in light of growing global demand and supply challenges. The acquisition of DiabTec is a direct response to this need. This move not only strengthens Mubadala's and the UAE's life sciences sector but also underscores our commitment to improving global health outcomes by contributing to a more secure and sustainable insulin analogue supply chain.'
Sheikh Saqer Bin Humaid Al Qasimi, Chairman of the Board, Julphar, said: 'The sale of this facility is a further step in Julphar's strategy to divest non-core assets. Julphar supports Mubadala's initiative to strengthen the pharmaceutical sector in the United Arab Emirates and to build broader API manufacturing capabilities in the country.'
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Trade Arabia
4 hours ago
- Trade Arabia
Mubadala, Taqa complete acquisition of 875MW Uzbek power plant
Abu Dhabi sovereign investor Mubadala has announced that it has teamed up with Abu Dhabi National Energy Company (Taqa) for acquiring a gas-fired power generation plant at the Talimarjan Power Complex in Uzbekistan. Mubadala and Taqa each hold a 40% stake in the 875 MW TPP1 combined-cycle gas-fired plant through a newly established project company, Talimarjan Power Plant 1. The 875 MW TPP1 plant has a Power Purchase Agreement (PPA) with JSC 'Uzenergosotish' (UES) (successor power purchaser to National Electric Grid of Uzbekistan (JSC) for 25 years and plays a critical part in meeting demand for electricity in Uzbekistan as the country continues to experience rapid population and economic growth. Both Mubadala and Taqa each have a 40% stake in the Talimarjan Operations & Maintenance (O&M), which was established to operate the plant, while Uzbekistan's 'Talimarjan Issiqlik Elektr Stansiyasi' (TIES) holds the remaining 20% stakes in both the project company and the O&M entity. Hammad Rahman, Head of Asia Pacific Infrastructure at Mubadala, said: "Mubadala is committed to supporting countries across the world to meet their energy needs while reducing carbon emissions. Efficient natural gas-fired powered plants such as TPP1 will play an important part in enabling the transition to cleaner sources of energy." He pointed out that Uzbekistan was recording a significant growth in demand for power, and Mubadala looked forward to working with Taqa and its local partner TIES to ensure communities and businesses across the country have access to reliable, affordable and secure power supply that supports progress and socioeconomic development. Frank Possmeier, Chief Investment Officer, Generation at Taqa, said: "We are pleased to collaborate with Mubadala and TIES in acquiring this vital asset that plays a crucial role in Uzbekistan's journey towards a privatised energy sector." This transaction supports investments into the privatisation of Uzbekistan's power sector. It follows a strategic partnership between the governments of Uzbekistan and the UAE whereby Mubadala and Taqa will bring their global power sector expertise to the local power market in Uzbekistan. "As a low carbon power and water champion, Taqa will leverage its extensive experience and expertise to help Uzbekistan meet its growing energy needs while continuing to invest in this critical sector," he stated. "Our stake in TPP1 demonstrates progress in delivering on our 2030 targets which aim to grow our power generation capacity to 150 GW and strengthens our operation and maintenance capabilities which is also a pivotal element of our strategy. We are committed to enhancing efficiency and ensuring TPP1 runs as a world-class power plant as part of our expanding portfolio as we continue to provide power to the communities we serve," he added.
Trade Arabia
20 hours ago
- Trade Arabia
Abu Dhabi's data centre industry power investments to hit $10bn
Abu Dhabi National Energy Company (Taqa) is poised to significantly bolster Abu Dhabi's burgeoning data and artificial intelligence hub, with its CEO and Managing Director announcing that total investments to support the power needs of the data centre industry in the emirate will exceed AED37 billion. This announcement aligns with Taqa's broader strategy to provide clean, certified, and reliable energy for critical infrastructure. Speaking to the Wam on the sidelines of the World Utilities Congress 2025, Taqa Group CEO and Managing Director Jasim Husain Thabet hlighted the company's robust growth and strategic acquisitions. With a market capitalisation estimated at approximately AED360 billion, TAQA stands among the top five companies in Europe, Africa, and the Middle East for electricity generation, transmission, and water desalination, operating across 25 countries. Over the past four years, TAQA has impressively doubled its electricity production capacity to 56 gigawatts, surpassing the total electricity consumption of the United Kingdom. Recent strategic moves include the acquisition of an 875-megawatt gas-powered electricity station in Uzbekistan, in partnership with Mubadala, supporting Uzbekistan's energy transition and opening new Central Asian markets. Additionally, TAQA's acquisition of "Transmission Investment", a leading UK-based energy and utility investment platform. Further enhancing its clean energy portfolio, TAQA is currently constructing a 1-gigawatt gas turbine power station. In collaboration with Masdar, where TAQA holds a major stake, the company is also developing 5 gigawatts of solar energy backed by 19 gigawatt-hours of battery storage. This integrated solar and battery system, designed to deliver a continuous supply of 1 gigawatt for 24 hours, will be the largest project of its kind globally. Taqa aims to invest AED75 billion by 2030 to triple its electricity generation capacity to 150 gigawatts, he said.
Gulf Insider
22-05-2025
- Gulf Insider
FDA No Longer Recommends COVID Vaccine For Healthy Babies
The U.S. government no longer recommends the COVID-19 vaccine for healthy babies thanks to new guidelines from the Trump administration, which said Tuesday it will limit approval for seasonal COVID-19 shots to seniors and others at high risk pending more data on everyone else. Top officials for the Food and Drug Administration laid out new standards for updated COVID shots, saying they'd continue to use a streamlined approach to make them available to adults 65 and older as well as children and younger adults with at least one high-risk health problem. But the FDA framework, published Tuesday in the New England Journal of Medicine, urges companies to conduct large, lengthy studies before tweaked vaccines can be approved for healthier people. Previously, federal policy recommended an annual COVID shot for all Americans six months and older. In the paper and a subsequent online webcast, the FDA's top vaccine official said more than 100 million Americans still should qualify for what he termed a booster under the new guidance. Dr. Vinay Prasad described the new approach as a 'reasonable compromise' that will allow vaccinations in high-risk groups to continue while generating new data about whether they still benefit healthier people. 'For many Americans we simply do not know the answer as to whether or not they should be getting the seventh or eighth or ninth or tenth COVID-19 booster,' said Prasad, who joined the FDA earlier this month. He previously spent more than a decade in academia, frequently criticizing the FDA's handling of drug and vaccine approvals. It's unclear what the upcoming changes mean for people who may still want a fall COVID-19 shot but don't clearly fit into one of the categories. Provisional data from the Centers for Disease Control and Prevention shows more than 47,000 Americans died from COVID-related causes last year. The virus was the underlying cause for two-thirds of those and it was a contributing factor for the rest. Health experts say there are legitimate questions about how much everyone still benefits from yearly COVID vaccination or whether they should be recommended only for people at increased risk. In June, an influential panel of advisers to the CDC is set to debate which vaccines should be recommended to which groups.
